NervGen Bets Big on Neuro-Repair with Pivotal Spinal Cord Injury Trial

VANCOUVER, British Columbia – August 13, 2026 – In a strategic move that could reshape the future of neurological treatment, NervGen Pharma today announced it is set to begin its pivotal Phase 3 RESTORE study for spinal cord injury (SCI) this September. While the announcement was part of its second-quarter financial report, the true headline is the company’s decisive step forward, backed by a fortified balance sheet and key leadership appointments, to bring a potentially transformative therapy to a community with immense unmet need.

NervGen, a late-stage biopharmaceutical company, has secured a clear path forward with the U.S. Food and Drug Administration (FDA) for its lead candidate, NVG-291. With C$86.8 million (US$61.1 million) in cash reserves, the company is fully funded through the trial's expected completion, a critical milestone that de-risks the path to a potential market-changing data readout in 2028.

“With FDA alignment and funding to support RESTORE now in place, we have expanded our organization with experienced professionals who understand the operational demands of late-stage clinical development,” stated Adam Rogers, MD, President and CEO of NervGen. This strategic alignment of regulatory clarity, financial stability, and operational expertise signals that NervGen is not just advancing a clinical trial; it is building a foundation for a potential paradigm shift in neuroreparative medicine.

A Pivotal Moment for Spinal Cord Injury Treatment

The RESTORE study represents a beacon of hope for individuals living with chronic SCI. Unlike many trials that focus on the acute phase immediately following injury, RESTORE will enroll approximately 150 adults who are one to ten years post-injury. This focus on the chronic population—a group long told their condition was permanent—is a significant departure from historical research.

The trial is a randomized, double-blind, placebo-controlled study, the gold standard for clinical evidence. Participants will receive daily subcutaneous injections of NVG-291 or a placebo for 12 weeks. The primary goal is to measure a change in fine-motor hand function, assessed by the GRASSP Quantitative Prehension test. This endpoint was not chosen in a vacuum; it reflects a high-priority need identified through extensive collaboration with the FDA, clinicians, and the SCI community. For individuals with tetraplegia, regaining even a small degree of hand function can mean a monumental leap in independence and quality of life.

Key secondary endpoints will capture a broader picture of recovery, including global impressions of change from both patients and clinicians, measures of independence, and reductions in spasticity. Crucially, the study also includes blinded qualitative interviews to understand the lived experience of participants, ensuring that the clinical data is contextualized by what constitutes a truly meaningful change for patients.

The Science of Repair: Beyond Managing Symptoms

What sets NVG-291 apart is its fundamental approach. For decades, SCI treatment has focused on stabilization and rehabilitation—managing the injury rather than repairing it. NervGen's candidate is designed to be a first-in-class neuroreparative therapeutic, aiming to enable the central nervous system to heal itself.

NVG-291 targets an inhibitory pathway involving Chondroitin Sulfate Proteoglycans (CSPGs) that emerges after a spinal cord injury. These molecules form a 'glial scar' that blocks nerve regeneration. NVG-291 is engineered to modulate this pathway, effectively releasing the brakes on the nervous system’s innate repair mechanisms. This allows for axonal sprouting, remyelination, and enhanced plasticity, the biological processes essential for restoring lost function.

The confidence to launch a multi-year, multi-million-dollar Phase 3 study stems from compelling earlier results. The Phase 1b/2a CONNECT SCI study provided tantalizing evidence of NVG-291's potential. Independent, blinded analysis from that study showed statistically significant improvements in gait quality, including better coordination and postural stability. In fact, 100% of subjects receiving NVG-291 were classified as responders in a global statistical test, compared to just 10% in the placebo group. The data also showed remarkable improvements in hand function and patient-reported benefits in bladder control and spasticity, suggesting a systemic and durable effect.

Fortifying the Foundation: Capital and Leadership

A promising drug is only half the battle; executing a successful late-stage trial and navigating the path to commercialization requires immense capital and strategic expertise. NervGen has spent the last year methodically building this foundation. A US$60 million public offering earlier in the year bolstered its cash reserves, providing a clear runway through the anticipated RESTORE data readout in the first half of 2028. This financial security is paramount for investors and allows the clinical team to focus on execution without the distraction of near-term financing concerns.

Equally important are the recent leadership additions. The appointment of Keith Vendola, MD, MBA, as Chief Financial Officer brings a veteran of the biotech capital markets to the team. With a track record of leading IPOs and managing finances for clinical-stage companies, his expertise is tailor-made for NervGen’s current growth phase. Similarly, the hiring of Marissa Volpe as SVP, Clinical Development, strengthens the operational team responsible for steering the complex, multi-center RESTORE study to a successful conclusion.

These strategic personnel and financial moves demonstrate a corporate maturity that aligns with the advanced stage of its lead asset, positioning NervGen not as a speculative R&D firm, but as a company on the cusp of a major value inflection point.

Navigating a Competitive and Hopeful Landscape

The unmet need in spinal cord injury is vast. With only one approved therapy available exclusively in Japan, the global market is wide open for an effective treatment. This has attracted a number of competitors exploring everything from cell therapies to other drug candidates and device-based stimulation. However, NVG-291's unique mechanism, targeting the body's own repair systems, gives it a distinct and potentially powerful advantage.

NervGen is also demonstrating a commitment to transparency and community engagement. The company plans to host its inaugural R&D Day this fall, bringing together management and leading SCI experts to detail the science and strategy behind its programs. Furthermore, the timing of the RESTORE study's launch in September aligns with SCI Awareness Month and a significant externally-led Patient-Focused Drug Development meeting, underscoring the company’s alignment with the community it aims to serve.

As NervGen prepares to dose its first participant, it stands at a critical juncture. The convergence of promising science, robust funding, regulatory alignment, and a deeply committed patient community sets the stage for what could be one of the most important clinical trials in neurology in recent years.